Home > News > Nanotech Is in the Genes
September 24th, 2007
Nanotech Is in the Genes
Abstract:
When nanotech start-up Nanosphere last month announced its intention to go public, there was speculation that the move was just a prelude to a merger with one of its larger rivals in the field of molecular diagnostic testing.
The possibility of a merger just became a lot more likely. Why? Last week, the Food and Drug Administration approved a Nanosphere-made genetic test that will help patients better understand how they might metabolize the anti-blood clot medicine warfarin -- which is sold under the brand name Coumadin and is manufactured by Bristol-Myers Squibb (NYSE: BMY).
The importance of this event can't be overstated. According to a 2006 study, FDA economists have estimated genetic testing in this situation could prevent 85,000 "serious bleeding events" and 17,000 strokes a year. Total savings for the health care system could reach $1.1 billion.
Source:
fool.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||